Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EIKN | PRESS-RELEASE | bullish | 6/10 | Eikon Therapeutics presented updated Phase 2 data for its TLR7/8 agonist EIK1001 in first-line stage 4 NSCLC at ESMO 202 | Oct 26, 2026 |
| BNTX | PRESS-RELEASE | bearish | 6/10 | BioNTech and DualityBiologics announced that the Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan (BNT323/DB-130 | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in fir | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SAFFRON trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in ME | Oct 25, 2026 |
| ORKA | PRESS-RELEASE | neutral | 6/10 | Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in plaque | Oct 25, 2026 |
| AVBP | PRESS-RELEASE | bullish | 5/10 | ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, a CDH17-targeting ADC, in heavily pretreat | Oct 25, 2026 |
| AMRN | PRESS-RELEASE | mixed | 6/10 | Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver metastases | Oct 25, 2026 |
| NBP | PRESS-RELEASE | bullish | 7/10 | NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and 16.9- | Oct 25, 2026 |
| REGN | PRESS-RELEASE | bullish | 5/10 | Regeneron announced longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) in high-risk cuta | Oct 25, 2026 |
| BNTX | PRESS-RELEASE | bullish | 6/10 | BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-107 trial showing pumitamig plus docetaxel achieved a | Oct 25, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced publication of positive Phase 2/3 COMPANION-002 results for tovecimig in advanced biliary | Oct 24, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy a | Oct 24, 2026 |
| CLYM | PRESS-RELEASE | bullish | 7/10 | Climb Bio reported additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidney | Oct 23, 2026 |
| AVBP | PRESS-RELEASE | bullish | 7/10 | ArriVent announced that initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC ARR-217 (MRG00 | Oct 23, 2026 |
| PRFX | PRESS-RELEASE | neutral | 5/10 | PRF Technologies issued a shareholder letter highlighting a strengthened balance sheet with $11M cash and $2.5M liabilit | Oct 23, 2026 |
| ENLV | PRESS-RELEASE | neutral | 3/10 | Enlivex announced a 1-for-16 reverse stock split effective October 27, 2026, to regain compliance with Nasdaq listing re | Oct 22, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a 1-for-10 reverse stock split effective October 26, 2026, to regain compliance with Nasdaq' | Oct 22, 2026 |
| DYN | PRESS-RELEASE | neutral | 2/10 | Dyne Therapeutics granted inducement equity awards to 16 new hires, consisting of options for 290,100 shares and RSUs fo | Oct 22, 2026 |
| AARD | PRESS-RELEASE | bullish | 7/10 | FDA lifted the clinical hold on Aardvark's IND for ARD-101 in Prader-Willi Syndrome, allowing clinical development to re | Oct 22, 2026 |
| VOR | PRESS-RELEASE | bullish | 7/10 | Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, showing a statistically si | Oct 22, 2026 |
| ELUT | PRESS-RELEASE | neutral | 1/10 | Elutia Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| ANIK | PRESS-RELEASE | neutral | 1/10 | Anika Therapeutics Inc. announced it will report its Q3 2026 results on November 6, 2026. | Oct 22, 2026 |
| KYMR | PRESS-RELEASE | neutral | 1/10 | Kymera Therapeutics, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| DNLI | PRESS-RELEASE | neutral | 1/10 | Denali Therapeutics Inc. announced it will report its Q3 2026 results on November 3, 2026. | Oct 22, 2026 |
| KNSA | PRESS-RELEASE | neutral | 1/10 | Kiniksa Pharmaceuticals International, Plc announced it will report its Q3 2026 results on October 27, 2026. | Oct 22, 2026 |
| IFRX | PRESS-RELEASE | neutral | 3/10 | InflaRx presented pre-clinical data at Kidney Week 2026 showing izicopan reduced renal injury markers in two hamster kid | Oct 22, 2026 |
| VERA | PRESS-RELEASE | bullish | 8/10 | Vera Therapeutics announced positive final efficacy results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in IgA | Oct 22, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc subsidiary NeuroThera Labs announced completion of manufacturing and QP batch release certification for SCI-110 | Oct 22, 2026 |
| ERNA | PRESS-RELEASE | neutral | 3/10 | Ernexa Therapeutics released a Virtual Investor segment discussing its pre-IND interaction with the FDA for lead candida | Oct 22, 2026 |
| PROK | PRESS-RELEASE | neutral | 3/10 | ProKidney announced a virtual KOL event on October 27, 2026, featuring Dr. Katherine Tuttle to discuss new insights into | Oct 22, 2026 |